Last 48 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
West Pharmaceutical Services, Inc.'s quarterly P/E stands at 32.6x, down 28.3% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has expanded 7.0% YoY to 25.8x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 47.33 | 32.64 | 37.79 | 33.98 | 30.05 | 45.50 | 46.01 | 40.56 | 54.53 | 63.82 | 48.10 | 43.83 | 46.42 |
| — | -28.3% | -17.8% | -16.2% | -44.9% | -28.7% | -4.4% | -7.5% | +17.5% | +36.3% | +11.2% | +13.3% | +52.9% | |
| P/S Ratio | 7.55 | 5.37 | 6.21 | 5.93 | 5.20 | 5.85 | 8.06 | 7.37 | 8.65 | 10.57 | 9.02 | 9.45 | 9.56 |
| — | -8.2% | -23.0% | -19.6% | -39.9% | -44.6% | -10.6% | -22.0% | -9.6% | +15.4% | +43.6% | +39.3% | +28.7% | |
| P/B Ratio | 7.37 | 6.07 | 6.30 | 6.25 | 5.44 | 6.09 | 9.00 | 8.01 | 9.42 | 10.97 | 9.17 | 9.85 | 10.50 |
| — | -0.4% | -30.0% | -21.9% | -42.3% | -44.5% | -1.8% | -18.7% | -10.3% | +16.1% | +38.3% | +30.7% | +11.1% | |
| P/FCF | 49.48 | 96.11 | 28.58 | 35.61 | 39.08 | 70.32 | 70.84 | 55.75 | 93.66 | 266.32 | 50.63 | 52.59 | 76.86 |
| — | +36.7% | -59.7% | -36.1% | -58.3% | -73.6% | +39.9% | +6.0% | +21.9% | +127.4% | +54.7% | +25.5% | +43.5% | |
| EV / EBITDA | 30.77 | 25.79 | 23.98 | 21.62 | 19.69 | 24.11 | 28.35 | 26.26 | 35.56 | 44.75 | 31.31 | 30.49 | 32.02 |
| — | +7.0% | -15.4% | -17.7% | -44.6% | -46.1% | -9.5% | -13.9% | +11.1% | +38.9% | +40.3% | +45.7% | +44.4% | |
| EV / EBIT | 36.97 | 25.79 | 30.05 | 26.91 | 25.02 | 36.61 | 36.32 | 33.06 | 46.35 | 56.45 | 38.19 | 36.42 | 37.80 |
| — | -29.6% | -17.3% | -18.6% | -46.0% | -35.1% | -4.9% | -9.2% | +22.6% | +40.9% | +15.6% | +10.7% | +53.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
West Pharmaceutical Services, Inc.'s operating margin was 21.0% in Q1 2026, up 1.5 pp QoQ and up 2.6 pp YoY. Gross margin expanded 5.3% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.9% | 35.1% | 37.8% | 36.5% | 35.7% | 33.3% | 36.7% | 35.5% | 32.9% | 33.3% | 38.1% | 38.7% | 38.7% |
| — | +5.3% | +3.0% | +2.8% | +8.2% | +0.2% | -3.8% | -8.3% | -15.0% | -12.0% | +2.5% | -0.6% | -6.5% | |
| Operating Margin | 20.1% | 21.0% | 19.5% | 21.6% | 20.6% | 18.4% | 22.8% | 22.5% | 18.6% | 18.3% | 23.3% | 25.6% | 24.8% |
| — | +14.0% | -14.6% | -3.9% | +10.8% | +0.7% | -2.2% | -12.1% | -25.0% | -21.9% | +2.0% | -6.5% | -14.4% | |
| Net Margin | 16.1% | 16.4% | 16.4% | 17.4% | 17.2% | 12.9% | 17.4% | 18.2% | 15.9% | 16.6% | 18.7% | 21.6% | 20.6% |
| — | +27.7% | -5.6% | -4.4% | +8.5% | -22.4% | -7.1% | -15.6% | -22.9% | -15.2% | +28.7% | +22.8% | -15.8% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.9% | 4.5% | 4.2% | 4.7% | 4.7% | 3.3% | 4.8% | 5.1% | 4.2% | 4.1% | 4.8% | 5.7% | 5.6% |
| — | +34.5% | -11.4% | -8.3% | +10.9% | -19.3% | +0.5% | -11.2% | -24.6% | -19.1% | +19.3% | +16.6% | -29.2% | |
| ROA | 12.5% | 3.3% | 3.2% | 3.5% | 3.5% | 2.5% | 3.6% | 3.8% | 3.1% | 3.1% | 3.6% | 4.3% | 4.2% |
| — | +33.9% | -11.3% | -8.5% | +10.9% | -20.3% | -1.6% | -12.6% | -25.2% | -18.7% | +21.6% | +20.3% | -25.9% | |
| ROIC | 17.5% | 4.8% | 4.3% | 4.8% | 4.5% | 3.8% | 5.1% | 5.0% | 4.1% | 4.0% | 5.5% | 6.3% | 6.3% |
| — | +27.7% | -14.3% | -4.8% | +10.0% | -6.1% | -9.0% | -20.4% | -35.4% | -30.7% | -5.1% | -8.4% | -24.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
West Pharmaceutical Services, Inc.'s Debt/EBITDA ratio is 1.8x, up from 1.6x last quarter — comfortably within a safe range. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.11 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.11 | 0.12 | 0.11 | 0.11 | 0.11 | 0.11 |
| — | -6.4% | -10.3% | -11.9% | -14.1% | -1.2% | +5.1% | +3.5% | +6.4% | +1.0% | -9.4% | -11.9% | -17.4% | |
| Debt / EBITDA | 0.56 | 1.82 | 1.58 | 1.37 | 1.52 | 1.80 | 1.43 | 1.47 | 1.83 | 1.89 | 1.50 | 1.35 | 1.41 |
| — | +1.0% | +10.2% | -6.3% | -17.0% | -4.5% | -4.4% | +8.3% | +30.2% | +19.4% | -9.2% | -1.9% | +7.4% | |
| Current Ratio | 3.02 | 2.71 | 3.02 | 2.87 | 2.78 | 2.77 | 2.79 | 3.00 | 2.34 | 2.61 | 2.88 | 3.70 | 3.66 |
| — | -2.1% | +8.1% | -4.4% | +18.8% | +6.0% | -3.0% | -18.8% | -36.1% | -27.9% | -22.1% | -2.6% | +16.9% | |
| Quick Ratio | 2.34 | 2.04 | 2.34 | 2.18 | 2.08 | 2.03 | 2.11 | 2.23 | 1.68 | 1.95 | 2.24 | 2.89 | 2.78 |
| — | +0.5% | +11.1% | -2.0% | +24.1% | +4.2% | -5.6% | -22.9% | -39.7% | -30.1% | -22.9% | -0.1% | +15.8% | |
| Interest Coverage | 998.67 | — | — | 1741.00 | 1571.00 | 277.25 | — | 236.00 | 86.80 | 85.93 | 153.91 | 65.48 | 72.12 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying WST stock.
West Pharmaceutical Services, Inc.'s current P/E is 47.3x. The average P/E over the last 4 quarters is 33.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
West Pharmaceutical Services, Inc.'s current operating margin is 20.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking West Pharmaceutical Services, Inc.'s business trajectory between earnings reports.